Why Arena Pharmaceuticals Stock Sank in 2016

Why Arena Pharmaceuticals Stock Sank in 2016


The small-cap biotech's shares fell by a whopping 22.4% last year, according to data from S&P Global Market Intelligence . Arena's stock suffered from both the poor commercial performance of its prescription obesity medication Belviq that's marketed by Japan's Eisai Co.



from Biotech News